Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.6B
30M shares
52-week range
$17.11 – $73.30
67% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
www.anaptysbio.comNo one on the platform currently holds ANAB.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 90,900 | $5.0M |
No one on the platform has traded ANAB yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 157.0% | 25.6% | ||||
| Profit Margin % | -5.6% | -492.2% | -526.4% | |||
| Free Cash Flow Margin % | 8.4% | -328.6% | -378.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $68M | -66.6% | $-2.28 | $-4.39–$1.33 | — | 4 |
| 2027 | $136M | +98.8% | $2.86 | $-0.05–$4.40 | 19.1× | 4 |
| 2028 | $332M | +143.5% | $5.47 | $3.64–$9.27 | 10.0× | 4 |
| 2029 | $350M | +5.6% | $5.90 | $2.61–$8.28 | 9.3× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-12 | $-0.32 | $-1.84 | -475.0% |
| 2026-03-03 | $0.89 | $1.58 | +77.5% |
| 2025-11-04 | $-1.06 | $0.52 | +149.1% |
| 2025-08-07 | $-1.50 | $-1.34 | +10.7% |
| 2025-05-05 | $-1.30 | $-1.28 | +1.5% |
| 2025-02-27 | $-1.55 | $-0.72 | +53.5% |
| 2024-11-05 | $-1.65 | $-1.14 | +30.9% |
| 2024-08-05 | $-0.99 |
| $-1.71 |
| -72.7% |
| $1.6B |
| — |
| NRIXNurix Therapeutics, Inc. | $25.68 | -2.23% | $2.7B | — |
| OCSOculis Holding AG | $11.33 | -1.26% | $647M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ANAB ...any shares manipulated down 10 to 15 percent on Last friday...buy with both hands.... short killing festive to start for 3months very soon...
View on StockTwits ↗
Wolfe Research reiterated $ANAB Outperform-$78 and said -- ANAB Post-trial briefs. initial reaction. we like Anaptys's position. Maintain Outperform $GSK $MRK AZN BMY REGN MKKGY RHHBY ESALY Here's what Wolfe Research went on to say: https://x.com/Quantumup1/status/2094397377104712160?s=20
View on StockTwits ↗$ANAB ...citadel crooks wont have any edge if retails stop using scam brokers like Robinhood , trading 212... these scammers loan out retail investors shares to their crime partner citadel crooks without any borrowing cost..as soon as retail buy with them.. doesnt matter you using margin or non margin account....
View on StockTwits ↗$ANAB ....citadel crooks wont have any edge if retails stop using scam brokers like Robinhood , trading 212... these scamners loan out retail investors shares to their crime partner citadel crooks without any borrowing cost..as soon as retail buy with them.. doesnt matter you using margin or non margin account..
View on StockTwits ↗
$ANAB $TRAX - I tend to look at the combined price of these 2 companies because they are directly linked. Anaptys is the Royalties arm of the two after having spun off the R&D portion of the themselves into First Tracks bio in April 2026. The combined ceiling appears to be about $105 currently and the combined COYPT is currently $157 indicating about a 50% upside. Combined share price sits at ~$99 at the moment. Lots of cautious optimism ahead as we wait for ongoing revenue from GSK and Vanda collaborations, new pipeline approvals, and resolution to the Tesaro litigation (expected Jan 2027). A breakthrough of that $105 ceiling would be a positive sign. LT hold for me. I have owned ANAB since Jan 2018, DCAing and trading along the way so I'm in the black at the moment on the combined value. https://www.anaptysbio.com/financial-collaborations/our-partnerships/
View on StockTwits ↗
$ANAB AnaptysBio options imply 5.0% move in share price post-earnings Pre-earnings options volume in AnaptysBio is normal with calls leading puts 188:1. Implied volatility suggests the market is anticipating a move near 5.0%, or 0c, after results are released. Median move over the past eight quarters is 2.8%.
View on StockTwits ↗$ANAB Estimated ER date is today AH. Estimated EPS Forecast: -$0.13 to -$0.22. PREVIOUS Report: Released Q1 2026 results on May 12, 2026, with an EPS of -$1.84. Last quarter they completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business. Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda. Personally looking for $100+/share LT. Those that have held for awhile have definitely benefited from the spinoff. BTW - If you need to know your cost basis for each company (ANAB, TRAX) for tax purposes you can either use what your broker states or Form 8937 (https://ir.anaptysbio.com/irs-form-8937)
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.